Lukemaviir

Lukemaviir is a medication used to treat chronic hepatitis C infection. It is a direct-acting antiviral (DAA) that works by inhibiting the hepatitis C virus (HCV) NS5A protein, which is essential for viral replication. Lukemaviir is typically used in combination with other DAAs, such as glecaprevir/pibrentasvir or sofosbuvir/velpatasvir, to achieve a sustained virologic response (SVR) in patients with genotype 1 HCV infection.

The most common side effects of lukemaviir include headache, fatigue, and nausea. Serious side effects are rare but can include allergic reactions, liver problems, and increased risk of liver cancer. Lukemaviir should be used with caution in patients with a history of liver disease or those who are unable to metabolize the medication properly.

Lukemaviir was approved by the U.S. Food and Drug Administration (FDA) in 2014 and has since been approved in many other countries for the treatment of chronic hepatitis C. It is available in tablet form and is typically taken orally once daily. The dosage and duration of treatment may vary depending on the specific combination of DAAs used and the patient's individual response to the medication.